KR20230117591A - 통증 경감을 위한 오피오이드 진통제 및 항경련제를함유하는 안정한 코팅된, 고형의 약학적 조성물 - Google Patents

통증 경감을 위한 오피오이드 진통제 및 항경련제를함유하는 안정한 코팅된, 고형의 약학적 조성물 Download PDF

Info

Publication number
KR20230117591A
KR20230117591A KR1020237022683A KR20237022683A KR20230117591A KR 20230117591 A KR20230117591 A KR 20230117591A KR 1020237022683 A KR1020237022683 A KR 1020237022683A KR 20237022683 A KR20237022683 A KR 20237022683A KR 20230117591 A KR20230117591 A KR 20230117591A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
composition according
pregabalin
derivatives
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237022683A
Other languages
English (en)
Korean (ko)
Inventor
쎄실리아 자넷 무노즈 말티네즈
요르게 알레잔드로 곤잘레스 카누다스
파올라 야즈민 올레비데스 루비오
시쓰토 세라핀 에스피노자 레온
에르네스토 츄아후텐코스 에스코바르
Original Assignee
라보라토리오스 실레인즈, 에스.에이. 드 씨.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=81853431&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20230117591(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 라보라토리오스 실레인즈, 에스.에이. 드 씨.브이. filed Critical 라보라토리오스 실레인즈, 에스.에이. 드 씨.브이.
Publication of KR20230117591A publication Critical patent/KR20230117591A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020237022683A 2020-12-04 2020-12-04 통증 경감을 위한 오피오이드 진통제 및 항경련제를함유하는 안정한 코팅된, 고형의 약학적 조성물 Pending KR20230117591A (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/MX2020/050050 WO2022119430A1 (es) 2020-12-04 2020-12-04 Composición farmacéutica sólida recubierta y estable de un analgésico opioide y un antiepiléptico para el dolor

Publications (1)

Publication Number Publication Date
KR20230117591A true KR20230117591A (ko) 2023-08-08

Family

ID=81853431

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237022683A Pending KR20230117591A (ko) 2020-12-04 2020-12-04 통증 경감을 위한 오피오이드 진통제 및 항경련제를함유하는 안정한 코팅된, 고형의 약학적 조성물

Country Status (10)

Country Link
US (1) US20240000727A1 (cg-RX-API-DMAC7.html)
EP (1) EP4230199A4 (cg-RX-API-DMAC7.html)
JP (1) JP7720911B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230117591A (cg-RX-API-DMAC7.html)
CA (1) CA3199166A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023008896A2 (cg-RX-API-DMAC7.html)
DO (1) DOP2023000095A (cg-RX-API-DMAC7.html)
MX (1) MX2022015331A (cg-RX-API-DMAC7.html)
PE (2) PE20252763A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022119430A1 (cg-RX-API-DMAC7.html)

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002091990A2 (en) 2001-05-14 2002-11-21 Brookhaven Science Associates Prevention of addiction in pain management
WO2006078811A2 (en) 2005-01-21 2006-07-27 Pharmanova Inc. Pharmaceutical formulations and methods of use
US20070052999A1 (en) 2005-07-06 2007-03-08 Kyocera Mita Corporation Image processing apparatus and image processing system
WO2008128775A2 (en) 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilised pharmaceutical composition containing pregabaline
EP2343055A1 (en) 2009-12-22 2011-07-13 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical compositions of pregabalin
MX2013000024A (es) 2010-07-06 2013-02-01 Gruenenthal Gmbh Nuevas formas de dosificacion gastrorretentivas.
US20130189354A1 (en) 2010-10-07 2013-07-25 Trinity Laboratories, Inc., Novel Pharmaceutical Compositions for Treating Chronic Pain and Pain Associated with Neuropathy
US20150313892A1 (en) 2014-02-07 2015-11-05 Trinity Laboratories, Inc. Pharmaceutical compositions for treating pain associated with dysmenorrhea
AU2017300185A1 (en) 2016-07-17 2019-01-24 Mapi Pharma Ltd. Extended release dosage forms of pregabalin
MX2017016720A (es) 2017-12-19 2019-06-20 Monte Verde S A Composición farmacéutica que contiene un analgésico de tipo opioide en combinación con un análogo del ácido g-aminobutírico (gaba).
WO2020044140A1 (es) 2018-08-30 2020-03-05 Grünenthal GmbH Combinación farmacéutica sinérgica que comprende tramadol clorhidrato y pregabalina, y su uso para el tratamiento del dolor neuropático

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637767A (en) 1995-06-07 1997-06-10 Warner-Lambert Company Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
RU2006118801A (ru) 2003-10-31 2007-12-10 Алза Корпорейшн (Us) Композиции и лекарственные формы для усиления всасывания габапентина и прегабалина
MXPA05011735A (es) 2005-11-01 2007-04-30 Leopoldo Espinosa Abdala Composiciones farmaceuticas que comprenden combinaciones de analgesicos y anticonvulsivantes para el tratamiento del dolor agudo y cronico.
EP2242737A1 (en) 2007-12-21 2010-10-27 Synthon B.V. Pregabalin salts
EP2575798B1 (en) * 2010-06-01 2017-08-09 Rubicon Research Private Limited Gastroretentive dosage forms of gaba analogs
KR20190075718A (ko) * 2017-12-21 2019-07-01 주식회사 네비팜 용출율이 개선된 트라마돌 또는 이의 약학적으로 허용가능한 염 및 프레가발린 또는 이의 약학적으로 허용가능한 염을 포함하는 다층 제제

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002091990A2 (en) 2001-05-14 2002-11-21 Brookhaven Science Associates Prevention of addiction in pain management
WO2006078811A2 (en) 2005-01-21 2006-07-27 Pharmanova Inc. Pharmaceutical formulations and methods of use
US20070052999A1 (en) 2005-07-06 2007-03-08 Kyocera Mita Corporation Image processing apparatus and image processing system
WO2008128775A2 (en) 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilised pharmaceutical composition containing pregabaline
EP2343055A1 (en) 2009-12-22 2011-07-13 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical compositions of pregabalin
MX2013000024A (es) 2010-07-06 2013-02-01 Gruenenthal Gmbh Nuevas formas de dosificacion gastrorretentivas.
US20130189354A1 (en) 2010-10-07 2013-07-25 Trinity Laboratories, Inc., Novel Pharmaceutical Compositions for Treating Chronic Pain and Pain Associated with Neuropathy
US20150313892A1 (en) 2014-02-07 2015-11-05 Trinity Laboratories, Inc. Pharmaceutical compositions for treating pain associated with dysmenorrhea
AU2017300185A1 (en) 2016-07-17 2019-01-24 Mapi Pharma Ltd. Extended release dosage forms of pregabalin
MX2017016720A (es) 2017-12-19 2019-06-20 Monte Verde S A Composición farmacéutica que contiene un analgésico de tipo opioide en combinación con un análogo del ácido g-aminobutírico (gaba).
WO2020044140A1 (es) 2018-08-30 2020-03-05 Grünenthal GmbH Combinación farmacéutica sinérgica que comprende tramadol clorhidrato y pregabalina, y su uso para el tratamiento del dolor neuropático

Also Published As

Publication number Publication date
PE20252763A1 (es) 2025-12-22
US20240000727A1 (en) 2024-01-04
PE20252750A1 (es) 2025-12-05
WO2022119430A1 (es) 2022-06-09
CO2023008896A2 (es) 2023-08-18
JP2024504902A (ja) 2024-02-02
EP4230199A4 (en) 2024-07-31
MX2022015331A (es) 2023-02-01
JP7720911B2 (ja) 2025-08-08
EP4230199A1 (en) 2023-08-23
CA3199166A1 (en) 2022-06-09
DOP2023000095A (es) 2023-06-15

Similar Documents

Publication Publication Date Title
MXPA02011610A (es) Combinacion de sustancia activa que contiene un opioide que tiene una estructura tipo fentanilo y cetamina.
US20080026054A1 (en) Novel anelgesic combination
CA2713365A1 (en) Stabilized sustained release composition of bupropion hydrochloride and process for preparing the same
US20160354335A1 (en) Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
US20120177735A1 (en) Oral dosage formulation containing both immediate-release and sustained-release drugs for treating neurodegenerative disorders
US20060153925A1 (en) Novel solid pharmaceutical composition comprising amisulpride
WO2019219920A1 (en) Stable pharmaceutical compositions of dpp-iv inhibitors in combination with metformin in the form of immediate release tablets
US20240307310A1 (en) Stabilized solid oral pharmaceutical composition of varenicline
JP7720911B2 (ja) 痛みに対するオピオイド鎮痛薬と抗てんかん薬のコーティングされた安定な固体医薬組成物
JP5386478B2 (ja) パーキンソン病に伴う運動不全の治療のための4−シクロプロピルメトキシ−n−(3,5−ジクロロ−1−オキシドピリジン−4−イル)−5−(メトキシ)ピリジン−2−カルボキサミドの使用
WO2014035355A1 (en) Pharmaceutical combination comprising idebenone and memantine
HU225779B1 (en) Pharmaceutical composition containing paracetamol and drotaverine and process for producing it
JP2020073583A (ja) ミューオピオイド受容体アンタゴニストとオピオイド剤との組み合わせ剤形
JP7336528B2 (ja) ネフォパムおよびアセトアミノフェンを含む薬学的組成物の製造方法、およびそれによって得られる薬学的組成物
US20230414545A1 (en) Fixed combination medicine for the control and management of neuropathic pain
US20250228797A1 (en) Synergic and stable pharmaceutical composition of an nsaid and an opioid analgesic for pain and inflammation
US11857684B2 (en) Oral bilayer tablets comprising acetylsalicylic acid and pseudoephedrine, methods of preparing and using thereof
ES2952013T3 (es) Combinación de ibuprofeno y tramadol para aliviar el dolor
CA3061243C (en) Idalopirdine-based combinatorial therapies of alzheimer's disease
US20050064029A1 (en) Stable pharmaceutical composition
US20130209553A1 (en) Extended release pharmaceutical compositions of pramipexole
EA049532B1 (ru) Фармацевтическая композиция, включающая мемантин и цитиколин
CA3088715A1 (en) Baclofen and acamprosate based therapy of alzheimer's disease in patients having lost responsiveness to acetylcholinesterase inhibitor therapy
WO2011042793A1 (en) Stabilized pharmaceutical composition comprising gabapentin with minimum levels of pharmaceutically acceptable inert excipients
BR102014003686B1 (pt) Composição farmacêutica oral estável

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000